Boston Scientific (BSX) Net Income towards Common Stockholders (2009 - 2026)

Boston Scientific has disclosed Net Income towards Common Stockholders across 18 years of filings, most recently posting $907.0 million for Q2 2026.

• In Q2 2026, Net Income towards Common Stockholders rose 13.8% year-over-year to $907.0 million; the TTM figure through Jun 2026 stood at $3.7 billion (up 46.71% YoY), while the FY2025 annual figure was $2.9 billion, up 56.4% from the prior year.
• Net Income towards Common Stockholders came in at $907.0 million for Q2 2026 at Boston Scientific, down from $1.3 billion in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $1.3 billion in Q1 2026 to a low of $97.0 million in Q1 2022.
• Average Net Income towards Common Stockholders over 5 years is $511.8 million, with a median of $500.0 million recorded in 2023.
• Year-over-year, Net Income towards Common Stockholders plunged 70.34% in 2022 and soared 300.79% in 2023.
• Over 5 years, Net Income towards Common Stockholders stood at $126.0 million in 2022, then soared by 300.79% to $505.0 million in 2023, then increased by 11.88% to $565.0 million in 2024, then gained by 18.94% to $672.0 million in 2025, then jumped by 34.97% to $907.0 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were $907.0 million in Q2 2026, $1.3 billion in Q1 2026, and $672.0 million in Q4 2025.